At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
Cabozantinib S-malate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer
In Brief
A Phase 2 clinical trial evaluating Cabozantinib S-malate, Laboratory Biomarker Analysis, and 1 other intervention for Endometrial Adenosquamous Carcinoma and 9 related conditions. Completed, enrolled 102 participants across 19 sites in 2 countries.
Detailed Summary
This phase II trial studies how well cabozantinib s-malate works in treating patients with endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Metastatic Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Uterine Corpus Carcinosarcoma
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedSep 2013
Primary CompletionSep 2019
Study CompletionOct 2024
TodayJul 2026
First PostedSep 5, 2013
Enrollment StartMay 8, 2013
Primary CompletionSep 12, 2019
Study CompletionOct 24, 2024
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 12.8 years ago
Interventions
Cabozantinib S-malatedrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies